Takeda and frazier healthcare partners announce collaboration to launch hillevax, inc. to develop clinical stage norovirus vaccine candidate

Cambridge, mass. & menlo park, calif.--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (takeda) and frazier healthcare partners (frazier) today announced a collaboration to launch hillevax, inc. (hillevax), a biopharmaceutical company to develop and commercialize takeda's norovirus vaccine candidate. takeda has granted a license to hillevax for the exclusive development and commercialization rights to its norovirus vaccine candidate, hil-214 (formerly tak-214), worldw
TAK Ratings Summary
TAK Quant Ranking